US EditionAstrocyte Pharmaceuticals Announces Milestones in the Fight Against Concussions: Launch of Phase 2 Clinical Trial and New $3M NIH Grant
2 Articles
2 Articles
Astrocyte Pharmaceuticals Announces Milestones in the Fight Against Concussions: Launch of ...
GROTON, Conn., June 17, 2025 (GLOBE NEWSWIRE) -- Astrocyte Pharmaceuticals Inc., a clinical-stage biotechnology company today announced two major milestones that could change the way we protect brains from the damage caused by concussions and repeat head impacts
Astrocyte Pharmaceuticals Announces Milestones in the Fight Against Concussions: Launch of Phase 2 Clinical Trial and New $3M NIH Grant
GROTON, Conn., June 17, 2025 (GLOBE NEWSWIRE) -- Astrocyte Pharmaceuticals Inc., a clinical-stage biotechnology company today announced two major milestones that could change the way we protect brains from the damage caused by concussions and repeat head impacts - one of the most pressing health concerns for athletes, military personnel, and families around the world. The company has dosed the first patient in its Phase 2 clinical trial in athle…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
To view factuality data please Upgrade to Premium
